RO113557B1 - Derivati de pirimido/5,4-d/pirimidine trisubstituite si procedee pentru prepararea acestora - Google Patents
Derivati de pirimido/5,4-d/pirimidine trisubstituite si procedee pentru prepararea acestora Download PDFInfo
- Publication number
- RO113557B1 RO113557B1 RO94-01270A RO9401270A RO113557B1 RO 113557 B1 RO113557 B1 RO 113557B1 RO 9401270 A RO9401270 A RO 9401270A RO 113557 B1 RO113557 B1 RO 113557B1
- Authority
- RO
- Romania
- Prior art keywords
- group
- carbon atoms
- alkyl
- piperidino
- amino
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims description 19
- 238000000034 method Methods 0.000 title claims description 8
- -1 pyrrolidino, piperidino Chemical group 0.000 claims description 415
- 125000004432 carbon atom Chemical group C* 0.000 claims description 128
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- 150000001875 compounds Chemical class 0.000 claims description 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 63
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 46
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 239000000460 chlorine Chemical group 0.000 claims description 32
- 229910052801 chlorine Inorganic materials 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 31
- 229910052731 fluorine Inorganic materials 0.000 claims description 30
- 239000011737 fluorine Substances 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 26
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 25
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 24
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 24
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 24
- 125000003282 alkyl amino group Chemical group 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 18
- 125000001246 bromo group Chemical group Br* 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 18
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 15
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 14
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 9
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 9
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
- 150000003254 radicals Chemical class 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000003647 oxidation Effects 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000001589 carboacyl group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 230000009435 amidation Effects 0.000 claims description 4
- 238000007112 amidation reaction Methods 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 4
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 150000001879 copper Chemical class 0.000 claims description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical group O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims description 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000006842 cycloalkyleneimino group Chemical group 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 125000005184 naphthylamino group Chemical group C1(=CC=CC2=CC=CC=C12)N* 0.000 claims description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000005577 anthracene group Chemical group 0.000 claims 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000002844 melting Methods 0.000 description 54
- 230000008018 melting Effects 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 239000013543 active substance Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 229940009456 adriamycin Drugs 0.000 description 12
- 239000012362 glacial acetic acid Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- CCMKPVQTRQFFQH-UHFFFAOYSA-N n-benzyl-2-chloro-n-methyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(Cl)N=C2C=1N(C)CC1=CC=CC=C1 CCMKPVQTRQFFQH-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CEIXWJHURKEBMQ-UHFFFAOYSA-N Heliamine Chemical compound C1CNCC2=C1C=C(OC)C(OC)=C2 CEIXWJHURKEBMQ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- JPOXNPPZZKNXOV-UHFFFAOYSA-N bromochloromethane Chemical compound ClCBr JPOXNPPZZKNXOV-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940032007 methylethyl ketone Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- HTQWGIHCFPWKAS-UHFFFAOYSA-N 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CNCCC11C(=O)NCN1C1=CC=CC=C1 HTQWGIHCFPWKAS-UHFFFAOYSA-N 0.000 description 1
- AQHKGPWUIOAPHJ-UHFFFAOYSA-N 2,4,8-trichloropyrimido[5,4-d]pyrimidine Chemical compound N1=CN=C(Cl)C2=NC(Cl)=NC(Cl)=C21 AQHKGPWUIOAPHJ-UHFFFAOYSA-N 0.000 description 1
- ZCWPHDXKEDBCER-UHFFFAOYSA-N 2,5-diphenyl-2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=CC=CC=C1C1=[NH+]N(C=2C=CC=CC=2)N=N1 ZCWPHDXKEDBCER-UHFFFAOYSA-N 0.000 description 1
- CVXSNGXWRHLZFU-UHFFFAOYSA-N 2,8-dichloro-4-(3,4-dihydro-1h-isoquinolin-2-yl)pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=C(Cl)C2=NC(Cl)=NC(N3CC4=CC=CC=C4CC3)=C21 CVXSNGXWRHLZFU-UHFFFAOYSA-N 0.000 description 1
- ZESYFFOWIGNGIO-UHFFFAOYSA-N 2-(2-chloro-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-yl)-3,4-dihydro-1h-isoquinoline-6,7-diol Chemical compound C1C=2C=C(O)C(O)=CC=2CCN1C(C1=NC(Cl)=N2)=NC=NC1=C2N1CCOCC1 ZESYFFOWIGNGIO-UHFFFAOYSA-N 0.000 description 1
- IYGVKKSDSOSZJV-UHFFFAOYSA-N 2-[4-(dimethylamino)piperidin-1-yl]-n-[(4-methylphenyl)methyl]-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1CC(N(C)C)CCN1C1=NC(N2CCOCC2)=C(N=CN=C2NCC=3C=CC(C)=CC=3)C2=N1 IYGVKKSDSOSZJV-UHFFFAOYSA-N 0.000 description 1
- CHTRZHZLAMTTPH-UHFFFAOYSA-N 2-[4-(dimethylamino)piperidin-1-yl]-n-methyl-4-morpholin-4-yl-n-(naphthalen-1-ylmethyl)pyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1CC(N(C)C)CCN1C1=NC(N2CCOCC2)=C(N=CN=C2N(C)CC=3C4=CC=CC=C4C=CC=3)C2=N1 CHTRZHZLAMTTPH-UHFFFAOYSA-N 0.000 description 1
- DPXOGEZISMVCJW-UHFFFAOYSA-N 2-[4-(dimethylamino)piperidin-1-yl]-n-methyl-4-morpholin-4-yl-n-(naphthalen-2-ylmethyl)pyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1CC(N(C)C)CCN1C1=NC(N2CCOCC2)=C(N=CN=C2N(C)CC=3C=C4C=CC=CC4=CC=3)C2=N1 DPXOGEZISMVCJW-UHFFFAOYSA-N 0.000 description 1
- WZWPIQGNNNVPLT-UHFFFAOYSA-N 2-[4-(dimethylamino)piperidin-1-yl]-n-methyl-8-morpholin-4-yl-n-(naphthalen-1-ylmethyl)pyrimido[5,4-d]pyrimidin-4-amine Chemical compound C1CC(N(C)C)CCN1C1=NC(N(C)CC=2C3=CC=CC=C3C=CC=2)=C(N=CN=C2N3CCOCC3)C2=N1 WZWPIQGNNNVPLT-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- ZSEAGDSPEIYWOP-UHFFFAOYSA-N 2-chloro-4-morpholin-4-yl-n-(2-phenylethyl)pyrimido[5,4-d]pyrimidin-8-amine Chemical compound C=12N=CN=C(NCCC=3C=CC=CC=3)C2=NC(Cl)=NC=1N1CCOCC1 ZSEAGDSPEIYWOP-UHFFFAOYSA-N 0.000 description 1
- KPWHMHALXRBQKK-UHFFFAOYSA-N 2-chloro-4-morpholin-4-yl-n-(3-phenylpropyl)pyrimido[5,4-d]pyrimidin-8-amine Chemical compound C=12N=CN=C(NCCCC=3C=CC=CC=3)C2=NC(Cl)=NC=1N1CCOCC1 KPWHMHALXRBQKK-UHFFFAOYSA-N 0.000 description 1
- LGUFKWLGJFXHND-UHFFFAOYSA-N 2-chloro-n-(cyclohexylmethyl)-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C=12N=CN=C(NCC3CCCCC3)C2=NC(Cl)=NC=1N1CCOCC1 LGUFKWLGJFXHND-UHFFFAOYSA-N 0.000 description 1
- SMBOFEIJKBINQD-UHFFFAOYSA-N 2-chloro-n-(cyclohexylmethyl)-n-methyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(Cl)N=C2C=1N(C)CC1CCCCC1 SMBOFEIJKBINQD-UHFFFAOYSA-N 0.000 description 1
- OXBQYWGGRRCMIM-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)methyl]-n-methyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(Cl)N=C2C=1N(C)CC1=CC=C(Cl)C=C1 OXBQYWGGRRCMIM-UHFFFAOYSA-N 0.000 description 1
- GUUZIICWUODTQX-UHFFFAOYSA-N 2-chloro-n-[(4-methoxyphenyl)methyl]-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1=CC(OC)=CC=C1CNC1=NC=NC2=C(N3CCOCC3)N=C(Cl)N=C12 GUUZIICWUODTQX-UHFFFAOYSA-N 0.000 description 1
- SHLGAHGBEJLXLO-UHFFFAOYSA-N 2-chloro-n-[(4-methoxyphenyl)methyl]-n-methyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1=CC(OC)=CC=C1CN(C)C1=NC=NC2=C(N3CCOCC3)N=C(Cl)N=C12 SHLGAHGBEJLXLO-UHFFFAOYSA-N 0.000 description 1
- LVMWNRQZQGCHRD-UHFFFAOYSA-N 2-chloro-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)C1=NC=NC2=C(N3CCOCC3)N=C(Cl)N=C12 LVMWNRQZQGCHRD-UHFFFAOYSA-N 0.000 description 1
- AVKQCAIJQBKBKC-UHFFFAOYSA-N 2-chloro-n-methyl-n-[(4-methylphenyl)methyl]-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(Cl)N=C2C=1N(C)CC1=CC=C(C)C=C1 AVKQCAIJQBKBKC-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- MWTGBAURSCEGSL-UHFFFAOYSA-N 3-(benzylamino)propanenitrile Chemical compound N#CCCNCC1=CC=CC=C1 MWTGBAURSCEGSL-UHFFFAOYSA-N 0.000 description 1
- STBDXSALGFNTHC-UHFFFAOYSA-N 3-[benzyl-(2-chloro-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-yl)amino]propanenitrile Chemical compound C=12N=CN=C(N(CCC#N)CC=3C=CC=CC=3)C2=NC(Cl)=NC=1N1CCOCC1 STBDXSALGFNTHC-UHFFFAOYSA-N 0.000 description 1
- LEOGASIOPSSVQW-UHFFFAOYSA-N 3-[benzyl-[2-[4-(dimethylamino)piperidin-1-yl]-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-yl]amino]propanenitrile Chemical compound C1CC(N(C)C)CCN1C1=NC(N2CCOCC2)=C(N=CN=C2N(CCC#N)CC=3C=CC=CC=3)C2=N1 LEOGASIOPSSVQW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- PXSFRIGHWCHZSU-UHFFFAOYSA-N 4-(2,8-dichloropyrimido[5,4-d]pyrimidin-4-yl)morpholine Chemical compound C=12N=CN=C(Cl)C2=NC(Cl)=NC=1N1CCOCC1 PXSFRIGHWCHZSU-UHFFFAOYSA-N 0.000 description 1
- YZYXKCUCMUSEEV-UHFFFAOYSA-N 4-(2-chloro-8-phenylmethoxypyrimido[5,4-d]pyrimidin-4-yl)morpholine Chemical compound C=12N=CN=C(OCC=3C=CC=CC=3)C2=NC(Cl)=NC=1N1CCOCC1 YZYXKCUCMUSEEV-UHFFFAOYSA-N 0.000 description 1
- QZWNVKAAPZPYTK-UHFFFAOYSA-N 4-(2-chloropyrimido[5,4-d]pyrimidin-4-yl)morpholine Chemical compound ClC=1N=C(C2=C(N=1)C=NC=N2)N1CCOCC1 QZWNVKAAPZPYTK-UHFFFAOYSA-N 0.000 description 1
- HHQWKZLAQJGWCH-UHFFFAOYSA-N 4-(8-benzylsulfanyl-2-chloropyrimido[5,4-d]pyrimidin-4-yl)morpholine Chemical compound C=12N=CN=C(SCC=3C=CC=CC=3)C2=NC(Cl)=NC=1N1CCOCC1 HHQWKZLAQJGWCH-UHFFFAOYSA-N 0.000 description 1
- TVMJNVDCTPZWDF-UHFFFAOYSA-N 4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)pyrimido[5,4-d]pyrimidin-4-yl]morpholine Chemical compound COC=1C=C2CCN(CC2=CC=1OC)C=1N=C(C2=C(N=1)C=NC=N2)N1CCOCC1 TVMJNVDCTPZWDF-UHFFFAOYSA-N 0.000 description 1
- LGFWFHVAVVEHBR-UHFFFAOYSA-N 4-[2-chloro-8-(1,3-dihydroisoindol-2-yl)pyrimido[5,4-d]pyrimidin-4-yl]morpholine Chemical compound C=12N=CN=C(N3CC4=CC=CC=C4C3)C2=NC(Cl)=NC=1N1CCOCC1 LGFWFHVAVVEHBR-UHFFFAOYSA-N 0.000 description 1
- SOLYVVXYRWIQEK-UHFFFAOYSA-N 4-[2-chloro-8-(3,4-dihydro-1h-isoquinolin-2-yl)pyrimido[5,4-d]pyrimidin-4-yl]morpholine Chemical compound C=12N=CN=C(N3CC4=CC=CC=C4CC3)C2=NC(Cl)=NC=1N1CCOCC1 SOLYVVXYRWIQEK-UHFFFAOYSA-N 0.000 description 1
- YKIHZDMMGJUGTJ-UHFFFAOYSA-N 4-[2-chloro-8-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)pyrimido[5,4-d]pyrimidin-4-yl]morpholine Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1C(C1=NC(Cl)=N2)=NC=NC1=C2N1CCOCC1 YKIHZDMMGJUGTJ-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- XZGYPGBRTTWCGC-UHFFFAOYSA-N 4-pyrimido[5,4-d]pyrimidin-2-ylmorpholine Chemical compound C1COCCN1C1=NC=C(N=CN=C2)C2=N1 XZGYPGBRTTWCGC-UHFFFAOYSA-N 0.000 description 1
- XIVFWOPDLPZENU-UHFFFAOYSA-N 4-pyrimido[5,4-d]pyrimidin-4-ylmorpholine Chemical compound C1COCCN1C1=NC=NC2=CN=CN=C12 XIVFWOPDLPZENU-UHFFFAOYSA-N 0.000 description 1
- STWODXDTKGTVCJ-UHFFFAOYSA-N 4-pyrrolidin-1-ylpiperidine Chemical compound C1CCCN1C1CCNCC1 STWODXDTKGTVCJ-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- LGYLTTHVEZGXDY-UHFFFAOYSA-N 8-[8-[benzyl(methyl)amino]-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-2-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(N3CCC4(CC3)C(NCN4C=3C=CC=CC=3)=O)N=C2C=1N(C)CC1=CC=CC=C1 LGYLTTHVEZGXDY-UHFFFAOYSA-N 0.000 description 1
- MPTKBCFOPCKKMW-UHFFFAOYSA-N 8-n-benzyl-2-[4-(dimethylamino)piperidin-1-yl]-4-n,4-n-diethyl-8-n-methylpyrimido[5,4-d]pyrimidine-4,8-diamine Chemical compound N1=CN=C2C(N(CC)CC)=NC(N3CCC(CC3)N(C)C)=NC2=C1N(C)CC1=CC=CC=C1 MPTKBCFOPCKKMW-UHFFFAOYSA-N 0.000 description 1
- WMCHXIVYXRICAW-UHFFFAOYSA-N 8-n-benzyl-2-chloro-4-n,4-n-diethyl-8-n-methylpyrimido[5,4-d]pyrimidine-4,8-diamine Chemical compound N1=CN=C2C(N(CC)CC)=NC(Cl)=NC2=C1N(C)CC1=CC=CC=C1 WMCHXIVYXRICAW-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000334993 Parma Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- OOJYPCDXFPWXFL-UHFFFAOYSA-N [C].OC1=CC=CC=C1 Chemical class [C].OC1=CC=CC=C1 OOJYPCDXFPWXFL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- WKTWNXRXMYEOJM-UHFFFAOYSA-N ethyl 2-[benzyl-(2-chloro-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-8-yl)amino]acetate Chemical compound N=1C=NC2=C(N3CCCCC3)N=C(Cl)N=C2C=1N(CC(=O)OCC)CC1=CC=CC=C1 WKTWNXRXMYEOJM-UHFFFAOYSA-N 0.000 description 1
- AMSOHTIWMSCHFP-UHFFFAOYSA-N ethyl 2-[benzyl-[2-[4-(dimethylamino)piperidin-1-yl]-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-yl]amino]acetate Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(N3CCC(CC3)N(C)C)N=C2C=1N(CC(=O)OCC)CC1=CC=CC=C1 AMSOHTIWMSCHFP-UHFFFAOYSA-N 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 150000004800 hydroisoquinoline derivatives Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- MVOJNQIUKOCFRI-UHFFFAOYSA-N n,n-dibenzyl-2-chloro-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C=12N=CN=C(N(CC=3C=CC=CC=3)CC=3C=CC=CC=3)C2=NC(Cl)=NC=1N1CCOCC1 MVOJNQIUKOCFRI-UHFFFAOYSA-N 0.000 description 1
- SWQDHDJAIYSTRF-UHFFFAOYSA-N n,n-dimethyl-1-piperidin-4-ylmethanamine Chemical compound CN(C)CC1CCNCC1 SWQDHDJAIYSTRF-UHFFFAOYSA-N 0.000 description 1
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
- CXTFIHDRGAZRLY-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-[4-(dimethylamino)piperidin-1-yl]-n-methyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1CC(N(C)C)CCN1C1=NC(N2CCOCC2)=C(N=CN=C2N(C)CC=3C=CC(Cl)=CC=3)C2=N1 CXTFIHDRGAZRLY-UHFFFAOYSA-N 0.000 description 1
- WEJQQLAAKOHJRQ-UHFFFAOYSA-N n-[2-(2-chloro-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-yl)-3,4-dihydro-1h-isoquinolin-5-yl]acetamide Chemical compound C1CC=2C(NC(=O)C)=CC=CC=2CN1C(C1=NC(Cl)=N2)=NC=NC1=C2N1CCOCC1 WEJQQLAAKOHJRQ-UHFFFAOYSA-N 0.000 description 1
- OFEPYKKVPFBJPL-UHFFFAOYSA-N n-benzyl-2,4-dichloro-n-methyl-1h-pyrimido[5,4-d]pyrimidin-4-amine Chemical compound N1=C(Cl)NC2=CN=CN=C2C1(Cl)N(C)CC1=CC=CC=C1 OFEPYKKVPFBJPL-UHFFFAOYSA-N 0.000 description 1
- KXCXDESVYWWYMK-UHFFFAOYSA-N n-benzyl-2-[4-(dimethylamino)piperidin-1-yl]-n-methyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C1CC(N(C)C)CCN1C1=NC(N2CCOCC2)=C(N=CN=C2N(C)CC=3C=CC=CC=3)C2=N1 KXCXDESVYWWYMK-UHFFFAOYSA-N 0.000 description 1
- UIGJQLXXEQVOBS-UHFFFAOYSA-N n-benzyl-2-chloro-4-morpholin-4-yl-n-propan-2-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(Cl)N=C2C=1N(C(C)C)CC1=CC=CC=C1 UIGJQLXXEQVOBS-UHFFFAOYSA-N 0.000 description 1
- XYQALCZKBXGKAD-UHFFFAOYSA-N n-benzyl-2-chloro-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound C=12N=CN=C(NCC=3C=CC=CC=3)C2=NC(Cl)=NC=1N1CCOCC1 XYQALCZKBXGKAD-UHFFFAOYSA-N 0.000 description 1
- MHOWPDAVWDXATH-UHFFFAOYSA-N n-benzyl-2-chloro-n-methyl-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCCCC3)N=C(Cl)N=C2C=1N(C)CC1=CC=CC=C1 MHOWPDAVWDXATH-UHFFFAOYSA-N 0.000 description 1
- QATBPZUYTGYDPU-UHFFFAOYSA-N n-benzyl-2-chloro-n-methyl-8-morpholin-4-ylpyrimido[5,4-d]pyrimidin-4-amine Chemical compound N=1C(Cl)=NC2=C(N3CCOCC3)N=CN=C2C=1N(C)CC1=CC=CC=C1 QATBPZUYTGYDPU-UHFFFAOYSA-N 0.000 description 1
- PSZKCNBFRUQQOP-UHFFFAOYSA-N n-benzyl-n-methyl-4-morpholin-4-yl-2-(4-piperidin-1-ylpiperidin-1-yl)pyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(N3CCC(CC3)N3CCCCC3)N=C2C=1N(C)CC1=CC=CC=C1 PSZKCNBFRUQQOP-UHFFFAOYSA-N 0.000 description 1
- YVCXYSNLKSMLJI-UHFFFAOYSA-N n-benzyl-n-methyl-4-morpholin-4-yl-2-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimido[5,4-d]pyrimidin-8-amine;oxalic acid Chemical compound OC(=O)C(O)=O.N=1C=NC2=C(N3CCOCC3)N=C(N3CCC(CC3)N3CCCC3)N=C2C=1N(C)CC1=CC=CC=C1 YVCXYSNLKSMLJI-UHFFFAOYSA-N 0.000 description 1
- SQVDROSFXWVXCM-UHFFFAOYSA-N n-cyclohexyl-2-[4-(dimethylamino)piperidin-1-yl]-n-ethyl-4-morpholin-4-ylpyrimido[5,4-d]pyrimidin-8-amine Chemical compound N=1C=NC2=C(N3CCOCC3)N=C(N3CCC(CC3)N(C)C)N=C2C=1N(CC)C1CCCCC1 SQVDROSFXWVXCM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4325900A DE4325900A1 (de) | 1993-08-02 | 1993-08-02 | Trisubstituierte Pyrimido [5,4-d] pyrimidine zur Modulation der Multidrugresistenz, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RO113557B1 true RO113557B1 (ro) | 1998-08-28 |
Family
ID=6494272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RO94-01270A RO113557B1 (ro) | 1993-08-02 | 1994-07-27 | Derivati de pirimido/5,4-d/pirimidine trisubstituite si procedee pentru prepararea acestora |
Country Status (22)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| DE19608588A1 (de) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19608653A1 (de) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| USRE37234E1 (en) * | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
| US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
| US8309562B2 (en) * | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| CN1984660B (zh) * | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉 |
| DE102004002557A1 (de) * | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CN115650827B (zh) * | 2022-10-27 | 2024-03-15 | 戊言医药科技（上海）有限公司 | 用于一类蒽环类毒素衍生物的制备方法、中间体化合物及合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0023559B1 (de) * | 1979-07-03 | 1984-09-19 | Dr. Karl Thomae GmbH | 2-(Perhydro-1,4-diazino)-pyrimido(5,4-d)pyrimidine, ihre Herstellung und diese Verbindungen enthaltenden Arzneimittel |
| DE2931573A1 (de) * | 1979-08-03 | 1981-02-26 | Thomae Gmbh Dr K | Mittel zur bekaempfung des wachstums von krebszellen und dessen herstellung |
| DE3049207A1 (de) * | 1980-12-27 | 1982-07-29 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue trisubstituierte pyrimido (5,4-d) pyrimidine, ihre herstellung und ihre verwendung als arzneimittel |
| DE3423092A1 (de) * | 1984-06-22 | 1986-01-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue 8-alkylthio-2-piperazino-pyrimido(5,4-d) pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| DE3833392A1 (de) * | 1988-10-01 | 1990-04-05 | Thomae Gmbh Dr K | Verwendung von pyrimido(5,4-d)pyrimidinen zur verhinderung der primaeren und sekundaeren resistenz bei der chemotherapie und diese verbindungen enthaltende arzneimittel |
-
1993
- 1993-08-02 DE DE4325900A patent/DE4325900A1/de not_active Withdrawn
-
1994
- 1994-07-07 TW TW083106205A patent/TW251286B/zh active
- 1994-07-26 EP EP94111739A patent/EP0645390A1/de not_active Withdrawn
- 1994-07-27 RO RO94-01270A patent/RO113557B1/ro unknown
- 1994-07-28 BG BG98931A patent/BG98931A/bg unknown
- 1994-07-29 IL IL110509A patent/IL110509A/en not_active IP Right Cessation
- 1994-07-29 NZ NZ264133A patent/NZ264133A/en unknown
- 1994-07-29 SK SK915-94A patent/SK91594A3/sk unknown
- 1994-07-29 CA CA002129179A patent/CA2129179A1/en not_active Abandoned
- 1994-08-01 CN CN94114910A patent/CN1041091C/zh not_active Expired - Fee Related
- 1994-08-01 RU RU94028278/04A patent/RU94028278A/ru unknown
- 1994-08-01 ZA ZA945689A patent/ZA945689B/xx unknown
- 1994-08-01 HU HU9402253A patent/HUT70957A/hu unknown
- 1994-08-01 KR KR1019940018961A patent/KR950005828A/ko not_active Withdrawn
- 1994-08-01 JP JP6179359A patent/JPH0789963A/ja active Pending
- 1994-08-01 NO NO942853A patent/NO301479B1/no unknown
- 1994-08-01 FI FI943574A patent/FI943574A7/fi unknown
- 1994-08-01 PL PL94304512A patent/PL304512A1/xx unknown
- 1994-08-01 AU AU68813/94A patent/AU683888B2/en not_active Ceased
- 1994-08-02 CZ CZ941845A patent/CZ184594A3/cs unknown
- 1994-08-02 US US08/284,325 patent/US5618814A/en not_active Expired - Fee Related
- 1994-11-23 EE EE9400255A patent/EE9400255A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU94028278A (ru) | 1996-08-27 |
| AU683888B2 (en) | 1997-11-27 |
| HU9402253D0 (en) | 1994-09-28 |
| NO942853L (no) | 1995-02-03 |
| HUT70957A (en) | 1995-11-28 |
| CN1106405A (zh) | 1995-08-09 |
| TW251286B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1995-07-11 |
| JPH0789963A (ja) | 1995-04-04 |
| IL110509A (en) | 1998-01-04 |
| EP0645390A1 (de) | 1995-03-29 |
| CN1041091C (zh) | 1998-12-09 |
| ZA945689B (en) | 1996-02-01 |
| KR950005828A (ko) | 1995-03-20 |
| DE4325900A1 (de) | 1995-02-09 |
| CZ184594A3 (en) | 1995-02-15 |
| IL110509A0 (en) | 1994-10-21 |
| US5618814A (en) | 1997-04-08 |
| SK91594A3 (en) | 1995-04-12 |
| PL304512A1 (en) | 1995-02-06 |
| FI943574A0 (fi) | 1994-08-01 |
| NZ264133A (en) | 1996-05-28 |
| AU6881394A (en) | 1995-02-09 |
| CA2129179A1 (en) | 1995-02-03 |
| EE9400255A (et) | 1996-02-15 |
| NO301479B1 (no) | 1997-11-03 |
| BG98931A (en) | 1995-09-29 |
| FI943574A7 (fi) | 1995-02-03 |
| NO942853D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1994-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3330706B2 (ja) | キナゾリン誘導体、その製法及びこれを含有する抗癌作用を有する医薬組成物 | |
| CN104903321B (zh) | 作为激酶抑制剂的经取代三环苯并咪唑 | |
| JP4276376B2 (ja) | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 | |
| EP3312180B1 (en) | Use of pteridinone derivative serving as egfr inhibitor | |
| CN100540552C (zh) | 3-氰基喹啉衍生物、其制备方法及其医药用途 | |
| RO113557B1 (ro) | Derivati de pirimido/5,4-d/pirimidine trisubstituite si procedee pentru prepararea acestora | |
| WO1997003069A1 (en) | Heterocyclic compounds and pharmaceutical compositions containing them | |
| PT823900E (pt) | Derivados de quinazolina | |
| US20030040527A1 (en) | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | |
| NO175979B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive pteridiner | |
| CN101591322A (zh) | 细胞周期素依赖蛋白激酶抑制剂黄芩黄酮有机胺衍生物及其制法和用途 | |
| JP2003525940A (ja) | 抗−腫瘍活性を有する、１，８−ナフタルイミドイミダゾ〔４，５，１−ｄｅ〕アクリドン類 | |
| CN112851679B (zh) | 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用 | |
| CN107892691A (zh) | 2,8,9‑三取代‑9h‑嘌呤类化合物及其盐和应用 | |
| CN108329232A (zh) | 酰肼类衍生物及其应用 | |
| CN117384161A (zh) | 靶向降解cdk蛋白的化合物及其应用 | |
| CN105001167A (zh) | 1-取代苯基-3-（4-取代苯基氨基-6-喹唑啉基）脲类化合物及制备方法和用途 | |
| CN114634453B (zh) | 喹唑啉衍生物制备方法及其应用 | |
| CN116554165B (zh) | 四氢吡啶并嘧啶衍生物及其用途 | |
| TWI807343B (zh) | 取代喹唑啉類化合物、藥物組合物及應用 | |
| CN117756805A (zh) | 蝶啶酮衍生物作为rsk抑制剂及其应用 | |
| TWI406853B (zh) | Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法 | |
| WO2024183710A1 (zh) | 抑制kif18a的化合物及其用途 | |
| PL218484B1 (pl) | Pochodne chinazoliny i ich zastosowanie | |
| DE19502179A1 (de) | Trisubstituierte Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |